A team led by a University of Delaware researcher has identified the protein essential for eye lens development and clear vision. Without the protein, eyes will form cataracts; with it, lens cells are cleared and ready to see. The work is providing fundamental new knowledge on the basic underlying mechanisms involved in eye development.
Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa.
Houston Methodist researchers developed a new lab-on-a-chip technology that could quickly screen possible drugs to repair damaged neuron and retinal connections, like what is seen in people with macular degeneration or who’ve had too much exposure to the glare of electronic screens.
During Healthy Vision Month throughout the month of May, the American Academy of Ophthalmology is sharing valuable information about how to take care of your vision.
Joan W. Miller, M.D., the David Glendenning Cogan Professor and Chair of Ophthalmology at Harvard Medical School and the Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, will receive two prestigious awards recognizing her significant contributions to the field of retina and ophthalmology.
Researchers at the National Eye Institute have discovered cellular mechanisms that help the 13-lined ground squirrel survive hibernation. Their findings could be a step toward extending storage of human donor tissues awaiting transplantation and protecting traumatic brain injury patients who undergo induced hypothermia. NEI is part of the National Institutes of Health. The findings were published in the May 3 issue of Cell.
Eye inflammation and uveal effusion develop among patients taking anti-cancer immune checkpoint inhibitor therapy.
A recent study shows that a new eye drop may be a potentially effective treatment for seasonal eye allergies, a condition affecting millions of people worldwide. The findings will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3
NeuroVision Imaging Inc. has announced a Series C financing round of $15 million with an initial close of $11.2 million. The round is led by Wildcat Capital Management with funding from several new investment groups. The financing provides support for NeuroVision as it seeks validation and regulatory approval for its breakthrough, low-cost, noninvasive, eye imaging system for measuring retinal autofluorescence that can detect amyloid beta (Aβ) plaque in the eye.
The findings of two new studies may help advance the diagnosis and treatment of eye cancers. The research is being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Two new research studies demonstrate that imaging technologies can help to diagnose and detect the progression of glaucoma, one of the leading causes of blindness in the U.S. When diagnosed early, vision loss from glaucoma can be slowed or prevented. The two studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Approach could guide research for inherited blindness treatment in humans
Researchers from around the world are sharing the latest high-tech advances in research to treat, diagnose and prevent diseases causing vision loss. The new findings demonstrate the impact of technology on vision and on vision science. The five studies will be presented in a news conference — virtually and onsite — at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, on Tuesday, May 1 at 9am.
GRF has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure.
In a new study, vision researchers found that certain types of lightbulbs and reading at different times of the day may contribute to nearsightedness, a condition clinically referred to as myopia. In another study, scientists found that a common food flavoring may offer new treatment options for reducing nearsightedness. The findings from the three new studies are being presented at the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
Three new studies demonstrate research findings that could offer novel treatments for vision and eye conditions. The studies will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, from Sunday, April 29 – Thursday, May 3.
Two new studies demonstrate potential future opportunities to use genetic information to treat vision conditions. The new studies are being presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
USC Roski Eye Institute scientists will present research on everything from nanophotoswitches and lipid nanoparticles to mapping the part of the brain responsible for visual processing at the ARVO 2018 annual meeting.
Research to Prevent Blindness has opened a new round of grants available to researchers across the country. This new round of grants significantly expands the pool of applicants who are eligible, by making a number of individual researcher awards available to researchers at all U.S. academic medical centers.
Orlando Health Physician Associates is deploying a device that will make it easier than ever for diabetes patients to check their eye health during regular visits to their primary care physicians.
Using new technologies to track how vision guides foot placement, researchers at The University of Texas at Austin come one step closer in determining what is going on in the brain while we walk, paving the way for better treatment for mobility impairments — strokes, aging and Parkinson’s — and technology development — prosthetics and robots.
Dr. Copeland dedicated his career to closing disparities in health care. Dr. Haile was chosen because she is forging a career path like Dr. Copeland’s. Currently, she is chief resident at California Pacific Medical Center’s Department of Ophthalmology/Lions Eye Clinic
UNLV scientist Kelly Tseng, Ph.D. and her team have found that frog embryos can fully regrow their eyes after injuries, a breakthrough that may lead one day to the ability to orchestrate tissue regeneration in humans.
By using a keyboard to provide tactile feedback along with a screen reader, users were three times more successful at navigating complex modern webpages, like an Airbnb booking site.
Although sight is a much different sense than sound, Georgetown University Medical Center neuroscientists have found that the human brain learns to make sense of these stimuli in the same way.
One risk of space flight is a possible danger to vision. Retired NASA astronaut David Wolf, M.D., will discuss how space flight affects eyes on in a keynote address at a conference of leading eye physicians and surgeons, hosted by the American Academy of Ophthalmology in Washington, D.C. April 19.
Results show supplement is no better than placebo in relieving signs and symptoms of disease.
Findings from a new randomized clinical trial, now show that contrary to a long held belief in the ophthalmic community, omega-3 supplements are no more effective than placebo at alleviating dry eye symptoms.
Omega-3 fatty acid supplements taken orally proved no better than placebo at relieving symptoms or signs of dry eye, according to the findings of a well-controlled trial funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Many people accept deteriorating eyesight as an inevitable part of getting older, but blurry or distorted vision – such as when straight lines appear wavy – could be signs of age-related macular degeneration.
There is no permanent cure for age-related macular degeneration (AMD), the leading cause of vision loss in adults ages 50 and older affecting about 10 million Americans.
Judith Smith, now 71, was at a routine appointment several years ago with her longtime ophthalmologist when the doctor made a comment that her right eye looked a little suspicious for glaucoma, an incurable disease that occurs when the optic nerve is damaged by pressure building inside the eye. Smith didn’t think she needed to worry about it since her doctor had just mentioned it in passing, so she put it out of her mind. A year later, when Smith returned for her checkup, her doctor was shocked to find that the optic nerve in her eye was already compromised and possibly permanently damaged.
It is most common in people 60 and older, but low vision can affect anyone at any age.
The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting is the largest gathering of eye and vision researchers in the world, with over 11,000 attendees from more than 75 countries. The five-day meeting will feature more than 6,000 poster and paper presentations of cutting-edge eye and vision research, offering an early glimpse into the latest advances in potential treatments for eye disease and blindness — often years ahead of their introduction to clinical practice.
A new Michigan State University study is the first to find that a particular type of lipid, or fat, thought to only exist in the skin, now lives in your eye and might play a major role in deterring diabetic retinopathy.
Studying mice and cells from patients, vision researchers at Washington University School of Medicine in St. Louis found that as immune cells called macrophages get older, they are more likely to contribute to inflammation and abnormal blood vessel growth in the back of the eye. This can damage vision in patients with age-related macular degeneration.
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell–based retinal implant is feasible for use in people with advanced dry age-related macular degeneration.
Massachusetts Eye and Ear researchers have shown that mifepristone, a drug currently FDA-approved for chemical abortion, prevents the growth of vestibular schwannoma (also known as acoustic neuroma) cells. This sometimes-lethal intracranial tumor typically causes hearing loss and tinnitus. The findings, published online today in Scientific Reports, suggest that mifepristone is a promising drug candidate to be repositioned for the treatment of these tumors.
Hackensack Meridian Health Riverview Medical Center located in Red Bank, today announced the re-launch of its eye care services in the Matthews Vision Treatment Center, located in the Ambulatory Care Center. The ophthalmic program offers the most up-to-date and advanced options available for vision correction.
Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). The cells also re-establish their normal organization and function.
Surgeons at Children’s Hospital Los Angeles treat the hospital’s first patient with gene therapy
Massachusetts Eye and Ear made medical history on Tuesday by performing the first post-FDA approval gene therapy for patients with a form of inherited blindness. The occasion marks the beginning of a new era in medicine, as it is the first time any FDA-approved gene therapy has been given to a patient for any inherited disease.
Automated reminder calls may be an effective tool to improve screening for diabetic eye disease among low-income minority patients, especially African Americans, a new study finds. The study results will be presented Monday at ENDO 2018, the Endocrine Society’s 100th annual meeting in Chicago, Ill.
The American Macular Degeneration Foundation (AMDF) and The Angiogenesis Foundation are partnering in a series of national initiatives designed to help people with age-related macular degeneration (AMD) get better care and treatment.
The most recent basic and clinical research developments related to the diagnosis and treatment of eye cancer will be the focus of a scientific meeting convened by the Association for Research in Vision and Ophthalmology (ARV0) in partnership with the Champalimaud Foundation. The Ocular Oncogenesis and Oncology Conference will be held July 18 – 21 at the Champalimaud Centre for the Unknown, a state-of-the-art medical and research facility located in Lisbon, Portugal
The ability of A.I. to help screen patients for a diabetic eye disease gains momentum with a study published today in Ophthalmology, the journal of the American Academy of Ophthalmology. Lily Peng, M.D., Ph.D., and colleagues at Google AI show they could improve disease-detecting software using a small subset of images adjudicated by ophthalmologists.
Glaucoma Research Foundation (GRF) announced today $720,000 in annual research grants to support 12 investigators at prestigious universities across the United States.
A new study from University of Michigan Kellogg Eye Center links familial relationships to the likelihood older adults will get needed cataract surgery — a procedure with broad implications for health.
People whose eyes show signs of small changes in blood vessels at age 60 may be more likely to develop thinking and memory problems by the time they are 80 than people with healthy eyes, according to a study published in the February 28, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right